CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...

Hundreds of a people who have chronic liver disease are being helped by an NHS trust's service that helps them attend vital ...

Investigator Award has been awarded to two surgeon-scientists at the National Cancer Centre Singapore (NCCS) to pursue novel research in liver cancer and head and neck cancers. Globally, liver cancer ...

Hepatocellular carcinoma (HCC) is an aggressive disease that accounts for 80%-90% of all primary liver cancers. Previous findings have shown fibroblast growth factor 19 (FGF-19) to be overexpressed in ...

A new study reveals that even low-dose, chronic exposure to air pollution can trigger liver inflammation, fibrosis, and metabolic disruptions, increasing the risk of fatty liver disease and other ...